The global clinical trials market reached an estimated $66.3 billion in 2025, according to Global Market Insights. That figure is expected to grow to $70.7 billion in 2026, propelled by rising chronic disease rates, expanded outsourcing to contract research organizations (CROs), and the rapid adoption of precision medicine across oncology and rare disease programs. This post breaks down the latest clinical trials market statistics for 2026, covering market size, regional splits, therapeutic areas, trial phases, and the companies running the show.
Clinical Trials Market Statistics 2026 – TL;DR
The clinical trials market is projected at $70.7 billion in 2026, up from $66.3 billion in 2025.
Phase III trials generated $32.1 billion in 2025, making them the most resource-heavy stage of drug development.
Oncology accounted for 38.3% of the clinical trials market in 2025, the largest therapeutic segment.
North America held 50.7% of global clinical trials market share in 2025, with the U.S. alone expected to hit $26.25 billion in 2026.
ClinicalTrials.gov now lists more than 500,000 registered clinical studies across 220+ countries.
How Big Is the Clinical Trials Market in 2026?
Global Market Insights pegged the clinical trials market at $66.3 billion in 2025. The projected 2026 value is $70.7 billion, reflecting a compound annual growth rate (CAGR) of 8.3% through 2035, when the market could reach $144.4 billion. Fortune Business Insights offers a slightly different estimate, placing the 2025 figure at $64.94 billion and the 2026 figure at $69.27 billion, with a 7.2% CAGR through 2034.
Regardless of which estimate you use, the trajectory is clear: the market is growing at a pace that outstrips most healthcare services segments. Rising R&D budgets from pharma and biotech companies are the primary driver. Pfizer alone spent $10.8 billion on R&D in 2024, while Novartis invested $10 billion in the same year.
Source: Global Market Insights (April 2026)
Clinical Trials Market Statistics by Region
North America continues to hold the largest share. Fortune Business Insights recorded $28.54 billion in North American revenue for 2025, capturing 43.9% of the global market. The U.S. alone is expected to reach $26.25 billion in 2026. Europe followed at $21.84 billion (33.6%), while Asia Pacific recorded $12.53 billion (19.3%).
Asia Pacific is the fastest-growing region, with multiple research firms citing a CAGR between 7.1% and 7.9% through the early 2030s. China registered 4,300 clinical trials in 2023 alone, a 26.1% jump from 2022. India, Thailand, and the Philippines are also seeing increased trial activity, driven by 30% to 40% lower per-patient costs compared to the U.S. and EU. These cost advantages are pulling sponsors eastward, particularly for late-stage oncology programs.
| Region | 2025 Revenue (USD Billion) | Market Share (%) | 2026 Projected (USD Billion) |
|---|---|---|---|
| North America | $28.54 | 43.9% | $30.27 |
| Europe | $21.84 | 33.6% | $23.10 |
| Asia Pacific | $12.53 | 19.3% | $13.71 |
| Rest of World | $2.03 | 3.2% | $2.19 |
Source: Fortune Business Insights
Clinical Trials Market Statistics by Phase
Phase III trials dominate clinical trials spending. Global Market Insights reported the Phase III segment at $32.1 billion in 2025, accounting for roughly half of total market revenue. These trials require thousands of participants across multiple geographies, long timelines, and extensive regulatory documentation before an agency like the FDA or EMA grants marketing authorization.
Phase II is growing faster in relative terms, with a 6.8% CAGR projected through 2031. Adaptive trial designs are shortening Phase II timelines for rare-disease and precision medicine candidates, making this stage more attractive for biotech sponsors. Phase I studies, meanwhile, are expected to grow at a 7.2% CAGR, fueled by the expanding pipeline of biologics and cell-and-gene therapies.
| Trial Phase | 2025 Market Share (%) | Key Characteristic |
|---|---|---|
| Phase I | ~12% | Safety testing, small cohorts (20-100 subjects) |
| Phase II | ~18% | Efficacy and dose-finding, 100-300 subjects |
| Phase III | ~53-55% | Large-scale validation, thousands of subjects |
| Phase IV | ~15% | Post-market surveillance after approval |
Source: Global Market Insights, Research Nester
Clinical Trials Market by Therapeutic Area
Oncology is the largest therapeutic area in the clinical trials market, holding a 38.3% share in 2025 according to Global Market Insights. The segment is growing at an 8.8% CAGR through 2035. Cancer’s complexity, the demand for targeted therapies, and the sheer volume of ongoing immuno-oncology programs keep this category well ahead of all others.
Central nervous system (CNS) disorders are emerging as the next high-growth segment. A 7.6% CAGR is projected, driven by Alzheimer’s research, neurodegenerative drug candidates, and growing mental health trial pipelines. Autoimmune and inflammatory diseases are also attracting larger budgets. The University of Chicago Medicine, for example, initiated a Phase II CAR T-cell therapy trial for autoimmune conditions in January 2025.
Source: Global Market Insights, Precedence Research
How Are Decentralized Clinical Trials Changing the Market?
Decentralized clinical trials (DCTs) are one of the fastest-moving segments. These models replace traditional site visits with telehealth, wearable monitoring devices, and electronic data capture, letting patients participate from home. The DCT market alone was valued at $9.1 billion in 2025 and is projected to grow at a 13% CAGR through 2032, reaching $21.4 billion.
Retention rates in decentralized models reach 85%, according to industry data, compared to much lower rates in traditional site-based trials. The FDA processed 1,690 PDUFA submissions in 2024, and much of that clinical evidence relied on some form of hybrid or virtual design. Biologics and precision medicines now represent 38% of all investigational assets, up from 29% five years ago, and these complex programs especially benefit from AI-driven monitoring and safety surveillance.
Who Are the Largest Clinical Trials Companies?
IQVIA leads the market with over 14% share in 2025. The top five CROs, which include IQVIA, LabCorp, ICON plc, Parexel, and Syneos Health, collectively control about 45% of the market. Thermo Fisher’s PPD division is also a major player, and the combined CRO revenue of these five firms accounts for roughly 42% of global contract research spending.
Consolidation activity continues. In January 2026, Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research to expand its oncology trial capabilities. Thermo Fisher committed $420 million to double its viral-vector manufacturing capacity by 2027, a move tied directly to the growing pipeline of cell-and-gene therapy trials.
| Company | 2025 Market Share | Headquarters |
|---|---|---|
| IQVIA | ~14% | Durham, NC, USA |
| LabCorp | ~9% | Burlington, NC, USA |
| ICON plc | ~8% | Dublin, Ireland |
| Parexel | ~7% | Durham, NC, USA |
| Syneos Health | ~7% | Morrisville, NC, USA |
Source: Global Market Insights
Clinical Trials Market Statistics: Service Type Breakdown
Outsourcing dominates. The outsourcing services segment held a 64.4% share in 2025, as more pharma and biotech companies rely on CROs for trial management, regulatory compliance, and site monitoring. Clinical trial monitoring alone accounted for 28.5% of total spend.
Decentralized trial services are growing the fastest within this category, with a projected 14.6% CAGR from 2026 to 2031. Laboratory services captured 24.6% of the market in 2025. The shift toward outsourcing lets smaller biotech firms access the same trial infrastructure as large pharma without building it in-house, which lowers the barrier to entry for new drug development programs.
Source: Global Market Insights, Precedence Research
What Is Driving Clinical Trials Market Growth?
Chronic disease prevalence is the primary factor. The World Health Organization reported in 2024 that one in three people globally suffer from neurological disorders. Cancer incidence continues to rise worldwide, and metabolic diseases like type 2 diabetes affect over 227 million people in Asia Pacific alone.
Government funding is also increasing. The U.S. National Institutes of Health invests most of its $48 billion annual budget in medical research. China’s 62 IND clearances in 2025 reflect an increasingly supportive regulatory environment in Asia. Europe’s Clinical Trials Regulation has cut average approval time to 10 months, enabling faster multi-country site activation.
FAQs
How much is the clinical trials market worth in 2026?
The global clinical trials market is projected at $70.7 billion in 2026, up from $66.3 billion in 2025, according to Global Market Insights.
Which region leads the clinical trials market?
North America leads with roughly 44% to 51% of global revenue, depending on the source. The U.S. alone accounts for $26.25 billion in 2026.
What is the fastest-growing therapeutic area in clinical trials?
Oncology holds the largest share at 38.3%, growing at an 8.8% CAGR. CNS disorders are the fastest-growing segment at a 7.6% CAGR through 2031.
Who is the largest company in the clinical trials market?
IQVIA holds over 14% market share. The top five CROs, including LabCorp, ICON, Parexel, and Syneos Health, collectively control about 45%.
How many clinical trials are currently registered worldwide?
ClinicalTrials.gov lists more than 500,000 registered studies across 220+ countries, with over 569,000 total registered clinical studies reported by industry sources.
Sources:
https://www.gminsights.com/industry-analysis/clinical-trials-market
https://www.fortunebusinessinsights.com/clinical-trials-market-106930
https://www.precedenceresearch.com/clinical-trials-market
https://www.towardshealthcare.com/insights/innovation-in-drug-development-calls-for-clinical-trials
With many years of professional experience within transnational corporations in different industries, Richard Jaimes has had the opportunity to lead people and organizations, investigate future topics, create strategies and innovations, consult senior management and translate insights into business advantages. Richard is also a long time senior consultant with Quantumrun Foresight.
